Vest Financial’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.9M Sell
56,627
-30,649
-35% -$11.4M 0.23% 132
2026
Q1
$25.6M Buy
87,276
+20,982
+32% +$6.9M 0.31% 121
2025
Q4
$23.2M Sell
66,294
-22,688
-25% -$7.67M 0.29% 122
2025
Q3
$28.8M Sell
88,982
-10,817
-11% -$3.36M 0.38% 112
2025
Q2
$38.8M Buy
99,799
+14,809
+17% +$5.96M 0.55% 96
2025
Q1
$37M Sell
84,990
-5,623
-6% -$2.26M 0.57% 89
2024
Q4
$33.4M Buy
90,613
+38,834
+75% +$16.3M 0.59% 99
2024
Q3
$26.9M Buy
51,779
+9,979
+24% +$5.33M 0.52% 104
2024
Q2
$22.6M Buy
41,800
+6,967
+20% +$3.68M 0.54% 93
2024
Q1
$18.1M Buy
34,833
+7,049
+25% +$3.51M 0.48% 110
2023
Q4
$13.1M Buy
27,784
+6,970
+33% +$3.22M 0.49% 88
2023
Q3
$9.06M Buy
20,814
+9,030
+77% +$4.1M 0.5% 79
2023
Q2
$5.24M Buy
11,784
+8,869
+304% +$4.09M 0.49% 91
2023
Q1
$1.34M Buy
2,915
+2,159
+286% +$1.03M 0.18% 108
2022
Q4
$388K Buy
+756
New +$384K 0.06% 81

Other funds holding ELV

Vest Financial's ELV Position: Q2 2026 in Review

Vest Financial reduced its Elevance Health (ELV) stake by 35% in Q2 2026, selling an estimated $11.4M and leaving 56,627 shares worth $21.9M. The position accounts for 0.23% of the portfolio, ranked #132.

Vest Financial first reported a position in ELV in Q4 2022 and has held it in 15 quarters since. The position peaked at $38.8M in Q2 2025. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Vest Financial held 56,627 shares of Elevance Health worth $21.9M as of Q2 2026.
  • Vest Financial sold 30,649 Elevance Health shares in Q2 2026, an estimated $11.4M.
  • Elevance Health made up 0.23% of Vest Financial's portfolio in Q2 2026, its #132 holding.
  • Vest Financial first reported a position in Elevance Health in Q4 2022 and has held it in 15 quarters since.
  • Vest Financial's Elevance Health position peaked at $38.8M in Q2 2025.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Vest Financial's 13F filing for Q2 2026, filed 24 Jul 2026.